JP2024532733A5 - - Google Patents

Info

Publication number
JP2024532733A5
JP2024532733A5 JP2024507878A JP2024507878A JP2024532733A5 JP 2024532733 A5 JP2024532733 A5 JP 2024532733A5 JP 2024507878 A JP2024507878 A JP 2024507878A JP 2024507878 A JP2024507878 A JP 2024507878A JP 2024532733 A5 JP2024532733 A5 JP 2024532733A5
Authority
JP
Japan
Prior art keywords
cancer
fluoro
pyrido
pyrrolidine
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024507878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039969 external-priority patent/WO2023018810A1/en
Publication of JP2024532733A publication Critical patent/JP2024532733A/ja
Publication of JP2024532733A5 publication Critical patent/JP2024532733A5/ja
Pending legal-status Critical Current

Links

JP2024507878A 2021-08-10 2022-08-10 複素環式化合物及び使用方法 Pending JP2024532733A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163231543P 2021-08-10 2021-08-10
US63/231,543 2021-08-10
US202163289578P 2021-12-14 2021-12-14
US63/289,578 2021-12-14
US202263299667P 2022-01-14 2022-01-14
US63/299,667 2022-01-14
PCT/US2022/039969 WO2023018810A1 (en) 2021-08-10 2022-08-10 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2024532733A JP2024532733A (ja) 2024-09-10
JP2024532733A5 true JP2024532733A5 (cg-RX-API-DMAC7.html) 2025-08-19

Family

ID=85200999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024507878A Pending JP2024532733A (ja) 2021-08-10 2022-08-10 複素環式化合物及び使用方法

Country Status (8)

Country Link
US (1) US20240417412A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384177A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024532733A (cg-RX-API-DMAC7.html)
AU (1) AU2022325858A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228338A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024001824A (cg-RX-API-DMAC7.html)
TW (1) TW202317566A (cg-RX-API-DMAC7.html)
WO (1) WO2023018810A1 (cg-RX-API-DMAC7.html)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
AU2022220678A1 (en) * 2021-02-09 2023-09-21 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US20240109918A1 (en) * 2022-05-04 2024-04-04 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
US20240116951A1 (en) * 2022-05-04 2024-04-11 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
AU2023265688A1 (en) 2022-05-06 2024-10-17 PAQ Therapeutics Inc. Kras g12d proteolysis targeting chimeras
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
AU2023320565A1 (en) 2022-08-05 2025-01-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
KR20250109197A (ko) 2022-11-21 2025-07-16 트리라인 바이오사이언시스, 인크. 스피로환식 디하이드로피라노피리미딘 KRas 억제제
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
WO2025006967A1 (en) 2023-06-30 2025-01-02 Bristol-Myers Squibb Company Kras inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
KR20260054710A (ko) 2023-08-17 2026-04-22 트리라인 바이오사이언시스, 인크. 스피로시클릭 디히드로피라노피리미딘 KRas 저해제
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
KR20260087586A (ko) 2023-10-03 2026-06-11 피에이큐 테라퓨틱스 인코포레이티드 Kras 단백질분해 표적화 키메라
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128172A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
CN103588792B (zh) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途
UA127968C2 (uk) * 2017-05-22 2024-02-28 Емджен Інк. Інгібітори g12c kras і способи їх застосування
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) * 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
AU2020369569B2 (en) * 2019-10-24 2026-06-18 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
EP4262807A4 (en) * 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
EP4332105A4 (en) * 2021-04-30 2025-05-28 Genfleet Therapeutics (Shanghai) Inc. PYRIDINO- OR PYRIMIDO-CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE
BR112023024906A2 (pt) * 2021-05-28 2024-02-15 Redx Pharma Plc Compostos
AU2022304939A1 (en) * 2021-06-30 2024-02-08 Shanghai Allist Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, and preparation method therefor, intermediate thereof, and application thereof

Similar Documents

Publication Publication Date Title
JP2024532735A5 (cg-RX-API-DMAC7.html)
JP2024532734A5 (cg-RX-API-DMAC7.html)
JP2025508703A5 (cg-RX-API-DMAC7.html)
JP2024517695A5 (cg-RX-API-DMAC7.html)
JP2024517693A5 (cg-RX-API-DMAC7.html)
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2024532734A (ja) 複素環式化合物及び使用方法
RU2019120986A (ru) Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
AU2015296322B2 (en) 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
EP3875078A1 (en) Compounds for the treatment of covid-19
JP2022527796A5 (cg-RX-API-DMAC7.html)
CN107667092B (zh) 作为fgfr4抑制剂的甲酰化n-杂环衍生物
EP3310779A1 (en) Compounds and compositions for inhibiting the activity of shp2
JP2005526072A5 (cg-RX-API-DMAC7.html)
JP2023509886A (ja) 環式化合物およびその使用方法
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
EP3571207A1 (en) Substituted dihydroimidazopyridinediones as mknk1 and mknk2 inhibitors
WO2015004024A1 (en) Substituted pyrazolo-pyridinamines
EP2951175A1 (en) Substituted pyrazolopyrimidinylamino-indazoles
AU2015366417A1 (en) Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors
JP2019504102A5 (cg-RX-API-DMAC7.html)
JP2024505890A (ja) がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
WO2011096490A1 (ja) イミダゾピリジン-2-オン誘導体
ES3034384T3 (en) Cyclic compounds and methods of using same
WO2025222187A1 (en) Compounds and uses thereof